Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC )

AIMS: To evaluate the relative importance of attributes driving obesity medication (OM) choice and preferences among individuals with overweight or obesity. MATERIALS AND METHODS: US adults with obesity or overweight and ≥ 1 obesity-related complication completed an online survey including a discrete-choice experiment (DCE) in October-November 2025. In the DCE, participants chose between 2 hypothetical, experimentally designed OM profiles with attributes/levels related to efficacy, cardiovascular (CV) risk reduction, side effects, administration (route/frequency), and dosing instruction requirements. In a fixed-choice comparison, participants chose between 2 predefined oral OM profiles. Relative preference weights for the DCE attribute levels were estimated using a random-parameters logit model to estimate attribute importance, tradeoffs, and predicted treatment choice. RESULTS: Among 800 participants (400 OM-naïve/400 OM-experienced, 400 injection-naïve/400 injection-experienced), the most important attributes were route of administration, average weight-loss percentage, CV risk reduction, and the proportion of people achieving ≥ 20% weight loss. Dosing instructions had the lowest relative importance. There was a preference for 1 OM profile (Treatment A-a hypothetical oral semaglutide-like profile) over the alternative OM profile (Treatment B-a hypothetical orforglipron-like profile), according to the responses from the DCE (84.2% vs. 15.8%) and the fixed-choice question (90.0% vs. 10.0%). Only 23.4% indicated that taking an OM treatment on an empty stomach and waiting 30 min to eat would be disruptive to their lives. Most (73.3%) OM-naïve participants were open to taking an oral OM. CONCLUSIONS: Individuals with overweight or obesity prioritise weight-loss efficacy, CV risk reduction, and oral administration in OM treatment decisions; dosing instruction requirements were of low importance.

Authors

Institutions

Publication Details

Journal
Diabetes Obesity and Metabolism
Published
2026-09-17
DOI
https://doi.org/10.1111/dom.71318
Primary Topic
Economic and Environmental Valuation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC )

Sara Tadesse-Bell, Jaime P. Almandoz, Kelley Myers, Victoria Divino et al.
Diabetes Obesity and Metabolism
Economic and Environmental Valuation
article

Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete‐Choice Experiment ( OPTIC )

Sara Tadesse-Bell, Jaime P. Almandoz, Kelley Myers, Victoria Divino, Beverly G. Tchang, Cannon Kent, Jigish Bhavsar, Andrea Traina
article en

Abstract

AIMS: To evaluate the relative importance of attributes driving obesity medication (OM) choice and preferences among individuals with overweight or obesity. MATERIALS AND METHODS: US adults with obesity or overweight and ≥ 1 obesity-related complication completed an online survey including a discrete-choice experiment (DCE) in October-November 2025. In the DCE, participants chose between 2 hypothetical, experimentally designed OM profiles with attributes/levels related to efficacy, cardiovascular (CV) risk reduction, side effects, administration (route/frequency), and dosing instruction requirements. In a fixed-choice comparison, participants chose between 2 predefined oral OM profiles. Relative preference weights for the DCE attribute levels were estimated using a random-parameters logit model to estimate attribute importance, tradeoffs, and predicted treatment choice. RESULTS: Among 800 participants (400 OM-naïve/400 OM-experienced, 400 injection-naïve/400 injection-experienced), the most important attributes were route of administration, average weight-loss percentage, CV risk reduction, and the proportion of people achieving ≥ 20% weight loss. Dosing instructions had the lowest relative importance. There was a preference for 1 OM profile (Treatment A-a hypothetical oral semaglutide-like profile) over the alternative OM profile (Treatment B-a hypothetical orforglipron-like profile), according to the responses from the DCE (84.2% vs. 15.8%) and the fixed-choice question (90.0% vs. 10.0%). Only 23.4% indicated that taking an OM treatment on an empty stomach and waiting 30 min to eat would be disruptive to their lives. Most (73.3%) OM-naïve participants were open to taking an oral OM. CONCLUSIONS: Individuals with overweight or obesity prioritise weight-loss efficacy, CV risk reduction, and oral administration in OM treatment decisions; dosing instruction requirements were of low importance.

Diabetes Obesity and Metabolism
Cornell University (US), Novo Nordisk (United States) (US), RTI Health Solutions (US), The University of Texas Southwestern Medical Center (US)
Good health and well-being
Openalex Percentile: Top 5%
Economic and Environmental Valuation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.